|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US5891434A
(en)
|
1991-06-17 |
1999-04-06 |
Centocor, Inc. |
Monoclonal antibodies to the APO-1 antigen
|
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
|
CA2109398A1
(en)
|
1992-10-30 |
1994-05-01 |
Alejandro A. Aruffo |
Extracellular matrix receptor ligands that modulate leukocyte function
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
DE4447484C2
(de)
|
1994-04-08 |
1997-07-17 |
Deutsches Krebsforsch |
Mittel zur Hemmung von Apoptose
|
|
DK0766745T3
(da)
|
1995-04-08 |
2002-11-25 |
Lg Chemical Ltd |
Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
|
|
US6306395B1
(en)
|
1996-05-02 |
2001-10-23 |
Mochida Pharmaceutical Co., Ltd. |
Fas antigen derivatives
|
|
US5985565A
(en)
|
1996-10-09 |
1999-11-16 |
Temple University-Of The Commonwealth System Of Higher Education |
Chronic fatigue syndrome diagnosis
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
JP4303883B2
(ja)
|
1997-09-18 |
2009-07-29 |
ジェネンテック・インコーポレーテッド |
ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
AU3369199A
(en)
|
1998-03-30 |
1999-10-18 |
Eli Lilly And Company |
Therapeutic applications of mature flint (mflint) polypeptides or opg3, a memberof the tnf receptor superfamily
|
|
EP1087993B1
(en)
|
1998-06-18 |
2008-04-02 |
Imed Ab |
Fas peptides and antibodies for modulating apoptosis
|
|
AU4603499A
(en)
*
|
1998-06-26 |
2000-01-17 |
Joergen Agnholt |
Methods of expanding and selecting disease associated t-cells
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
PT1606318E
(pt)
|
2003-03-26 |
2009-11-10 |
Deutsches Krebsforsch |
Proteínas de fusão de fc melhoradas
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
CA2585776A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
EP1851308B1
(en)
*
|
2005-02-02 |
2013-08-21 |
NewSouth Innovations Pty Limited |
Cd4+ cd25+ t-cells activated to a specific antigen
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
DK1877090T3
(da)
|
2005-05-06 |
2014-04-14 |
Providence Health System |
Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US7596024B2
(en)
|
2006-07-14 |
2009-09-29 |
Semiconductor Energy Laboratory Co., Ltd. |
Nonvolatile memory
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
KR20100014588A
(ko)
|
2007-02-27 |
2010-02-10 |
제넨테크, 인크. |
길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
ES2538122T3
(es)
|
2008-07-21 |
2015-06-17 |
Apogenix Gmbh |
Moléculas de una sola cadena de TNFSF
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US8664366B2
(en)
|
2009-01-09 |
2014-03-04 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
|
CA2755198A1
(en)
|
2009-03-13 |
2010-09-16 |
Mark L. Tykocinski |
Ox40/trail fusion proteins
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
US9646134B2
(en)
|
2010-05-25 |
2017-05-09 |
The Regents Of The University Of California |
Bambam: parallel comparative analysis of high-throughput sequencing data
|
|
KR102042253B1
(ko)
|
2010-05-25 |
2019-11-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
EP3409686B1
(en)
|
2012-07-18 |
2022-04-13 |
Apogenix AG |
Composition comprising a mixture of cd95-fc isoforms
|
|
EP2968525A4
(en)
|
2013-03-14 |
2016-10-26 |
Icahn School Med Mount Sinai |
MORBUS NEWCASTLE VIRUSES AND USES THEREOF
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
AU2014407539B2
(en)
|
2014-10-02 |
2020-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
|
|
JP6599450B2
(ja)
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
MX2019000180A
(es)
*
|
2016-06-28 |
2019-11-05 |
Geneius Biotechnology Inc |
Composiciones de células t para la inmunoterapia.
|
|
CN110612446B
(zh)
*
|
2017-03-31 |
2023-07-04 |
美国卫生和人力服务部 |
分离新抗原-特异性t细胞受体序列的方法
|
|
SG11202004116QA
(en)
*
|
2017-11-08 |
2020-06-29 |
Biontech Us Inc |
T cell manufacturing compositions and methods
|
|
WO2019183924A1
(en)
*
|
2018-03-30 |
2019-10-03 |
Syz Cell Therapy Co. |
Improved multiple antigen specific cell therapy methods
|
|
WO2019210131A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3113259A1
(en)
*
|
2018-09-27 |
2020-04-02 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
AU2020226498A1
(en)
*
|
2019-02-19 |
2021-10-14 |
Turnstone Biologics Corp. |
Methods for producing autologous T cells useful to treat cancers and compositions thereof
|
|
US20220177841A1
(en)
*
|
2019-03-29 |
2022-06-09 |
Myst Therapeutics Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|